What Neurogene Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 17 |
| Total trades | 1 | 22 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 756 | 70,056 |
| Disposed | 0 | 41,580 |
| Net activity | +756 | +28,476 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| McMinn Rachel | Chief Executive Officer | Sep 22 | Exercise / conversion · M | +756 | $25.32 | +$19.1K | 1,345,063 |
| Cvijic Christine Mikail | President and CFO | Jul 07 | Open-market sale · S | −4,200 | $36.13 | −$152K | 84,040 |
| Cvijic Christine Mikail | President and CFO | Jul 06 | Open-market sale · S | −600 | $36.02 | −$21.6K | 88,240 |
| Cvijic Christine Mikail | President and CFO | Jul 02 | Open-market sale · S | −1,530 | $35.23 | −$53.9K | 88,840 |
| Cvijic Christine Mikail | President and CFO | Jul 02 | Open-market sale · S | −2,531 | $34.58 | −$87.5K | 90,370 |
| Cvijic Christine Mikail | President and CFO | Jul 01 | Open-market sale · S | −739 | $34.06 | −$25.2K | 92,901 |
| Cvijic Christine Mikail | President and CFO | May 06 | Open-market sale · S | −4,800 | $32.44 | −$156K | 93,640 |
| Cvijic Christine Mikail | President and CFO | May 06 | Open-market sale · S | −4,800 | $30.07 | −$144K | 98,440 |
| Cvijic Christine Mikail | President and CFO | Mar 26 | Open-market sale · S | −2,558 | $21.62 | −$55.3K | 103,240 |
| Jordan Julie | Chief Medical Officer | Mar 26 | Sale for tax withholding · S | −828 | $21.89 | −$18.1K | 12,472 |
| McMinn Rachel | Chief Executive Officer | Mar 26 | Sale for tax withholding · S | −3,352 | $22.07 | −$74K | 1,344,307 |
| Cvijic Christine Mikail | President and CFO | Mar 13 | Open-market sale · S | −263 | $22.02 | −$5.79K | 105,798 |
| Cvijic Christine Mikail | President and CFO | Mar 13 | Open-market sale · S | −1,395 | $21.25 | −$29.6K | 106,061 |
| Cvijic Christine Mikail | President and CFO | Mar 13 | Open-market sale · S | −2,387 | $20.42 | −$48.7K | 107,456 |
| Cobb Stuart | Chief Scientific Officer | Mar 13 | Open-market sale · S | −148 | $22.08 | −$3.27K | 30,497 |
| Cobb Stuart | Chief Scientific Officer | Mar 13 | Open-market sale · S | −2,658 | $21.34 | −$56.7K | 30,645 |
| Cobb Stuart | Chief Scientific Officer | Mar 13 | Open-market sale · S | −3,991 | $20.41 | −$81.5K | 33,303 |
| Cvijic Christine Mikail | President and CFO | Feb 27 | Open-market sale · S | −4,800 | $25.11 | −$121K | 109,843 |
| Cvijic Christine Mikail | President and CFO | Feb 20 | Grant / award · A | +22,000 | — | — | 114,643 |
| McMinn Rachel | Chief Executive Officer | Feb 20 | Grant / award · A | +25,900 | — | — | 1,347,659 |
Loading...
